3-hydroxybutyrate alone or in combination for use in the treatment of critical care treatment

This invention relates generally to methods and compositions for the treatment or prevention of critical illness myopathy and critical illness polyneuropathy and of critical illness myopathy and critical illness polyneuropathy caused by critical illnesses including sepsis, severe sepsis, severe sepsis with septic shock, and particularly to the use of a combination of parenteral or enteral feeding with a 3-hydroxybutyrate.

Patent Publication Number: EP3558291

Year filing: 2017

Year approval: 2020

Year publication: 2019

Status: Requested

Technology domains: Pharmaceuticals

Validated for IOF-key: Yes

Attributed to: Associatie KULeuven